N

nandrolone, 479

National Cancer Institute-Working Group (NCI-WG), 237

National Comprehensive Cancer Network, 87 natural killer cell acute leukemia, 27-28 neoangiogenesis, 475 neutropenic enterocolitis (NE), 1162-1163 nitrogen mustard derivatives, 1089 9-nitro-20-(S)-camptothecin, 490 nitrosoureas, 1089 NK-cell lymphoma, 504, 510 nodal marginal zone lymphoma, 518 non-Hodgkin's lymphoma allogeneic hematopoietic stem cell transplantation in aggressive NHL patients, 690 concept of reduced-conditioning of, 694-695 donor lymphocytes infusions, 696 in failed auto PBSCT, 690 in follicular NHL patients, 690 rationale for, 690

therapy for specific subtypes of, 695-696 using reduced-conditioning of, 695 vs autologous SCT, 693-694 assessment of molecular response and minimal residual disease, 704-705

autologous hematopoietic cell transplantation for Burkitt's lymphoma, 680-681 follicular NHL, 677-679 mantle cell lymphoma, 675-677 peripheral T-cell lymphoma, 679-680 posttransplant consolidation and maintenance therapy, 681-682 risks after autografting, 682-683 follow up of, 708-709

histopathological reproductibility and clinical relevance of, 507-508

prognosis and prognostic factors of of diffuse large B-cell lymphoma, 705-706 of follicular lymphoma, 707-708 relative frequency of different lymphomas, 508 revised European American classification, 504 standard response criteria in, 701-703 therapies for antisense oligonucleotide therapy, 726-727 fusion toxins, 723-724 gallium nitrate therapy, 727-728 histone deacetylase inhibitors, 728 monoclonal antibody therapy for, 723 proteosome inhibitors, 728 radiolabeled antibody therapy, 724-726 tumor vaccines, 728-729 treatment approach to high-grade of Burkitt's lymphoma, 569-573

precursor B-cell and T-cell lymphoblastic lymphoma, 565-569 treatment of transformed clinical findings and outcomes, 712-714 conventional therapy for follicular lymphomas, 715-716 etiology of transformation, 714-715 incidence of histologic transformation, 711-713 monoclonal antibody therapy for follicular lymphomas, 716 of Richter's syndrome, 718-719 risk factors, 712

transplantation in follicular lymphomas, 716-718 use of functional imaging in response assessment in, 703-704 WHO classification, 504-505 basis of real and WHO classification, 505-506 issue relating to individual entities in, 508-510 structure of, 506-507 updating of, 508 nonlymphoid hematopoietic progenitors, 1 nonmyeloablative allogeneic stem cell transplantations, 59 nonmyeloablative stem cell transplantation, 661

in MMM, 476 nonspecific esterase (monocytic), 33 nonspecific esterase (NSE), 10 NPM gene, 87

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment